PlainPharmaWatch

CMS Open Payments · Program Year 2024

Reapplix Inc.

Reapplix Inc. reported $101,738.03 across General Payments, Research, and Ownership to 318 physicians and teaching hospitals across 318 transactions.

$101.7K
All-tracks total
318
Transactions
318
Recipients
+$41.1K
General Payments vs PY2023

Reapplix Inc. reported $101,738.03 across all CMS Open Payments tracks (General + Research + Ownership) to 318 physicians and teaching hospitals in Program Year 2024 - ranking #1182 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $101,738.03, averaging $319.93 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer reapplix-inc Reapplix Inc.

$101.7K · #1182/1,925 · 0.0% industry · PY2024

  • TOT $101.7K
  • RANK #1182
  • SHARE 0.0%
  • TXN 318
  • RCP 318
  • CAT 3
  • GEN $101.7K
  • ΔGEN +$41.1K
  • TOP1 49.9%
  • PY 2024

Nearest volume peer: Brahms GmbH ($101.8K)

Kowa Pharmaceuticals America…$101.9KBioPro, Inc.$101.9KShofu Dental Corp$101.9KBrahms GmbH$101.8KReapplix Inc. (this)$101.7K
All-tracks payment totals near Reapplix Inc. (CMS Open Payments PY2024)

Reapplix Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Reapplix Inc.'s CMS-reported General Payments increased by $41.1K (+67.7%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: REAPPLIX INC.PY2023: REAPPLIX INC.PY2024: Reapplix Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$60.7KPY2024$101.7K
PY2023
$60,664.71
PY2024
$101,738.03

What the Data Shows for Reapplix Inc.

$101,738.03: that is what Reapplix Inc. reported in payments to 318 physicians and teaching hospitals during Program Year 2024, spread across 318 transactions ($319.93 per transaction, $319.93 per recipient). The company sits at rank #1182 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Compensation for Services Other Than Consulting" leads the 3-category general-payment breakdown below at $46.8K (46.0% of General Payments, 9 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Reapplix Inc. made 3 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $46.8K, 46.0% of General Payments.

How Reapplix Inc. divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$46.8K2. Compensation for Faculty …$38.9K3. Food and Beverage$16.1K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $46.8K 9
Compensation for Faculty or Speaker (Medical Education) $38.9K 6
Food and Beverage $16.1K 303

Recipient Concentration in General Payments

The five largest recipient relationships account for $88,251.10 (86.7%) of $101,738.03 in this company's General Payments records across 203 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Reapplix Inc.

The five named recipients with the highest reported General Payments from this company

Tyson E Green$50.7KJames C Lin$20.5KAshley Rose Sonney$10.0KKara Springfield Couch$6.6KMarcus Clay Stokes$517.51
  1. 1

    Tyson E Green

    $50,741.08 across 22 reported transactions

  2. 2

    James C Lin

    $20,463.50 across 15 reported transactions

  3. 3

    Ashley Rose Sonney

    $9,971.60 across 2 reported transactions

  4. 4

    Kara Springfield Couch

    $6,557.41 across 6 reported transactions

  5. 5

    Marcus Clay Stokes

    $517.51 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Reapplix Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Reapplix Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Reapplix Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Reapplix Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.